Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Google Disrupts Major Residential Proxy Network IPIDEA 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
RALEIGH, N.C., May 22, 2017 -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the fourth consecutive year it was recognized as the International Clinical Research Company of the Year. PRA received the award at a PharmaTimes ceremony in London. This award follows PRA’s recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/29ac9b83-70bf-451e-a05f-bda1b8a05df8
“PRA is honored to once again receive this prestigious award,” said David Passov, Senior Vice President, Project Management EAPA. “It is recognition of our talented and dedicated employees and their passion to help others through their clinical development work.”
PRA won a total of three Gold, four Silver and five Bronze awards. Individual gold award recipients include:
- Clinical Trial Administrator of the Year: James Battisti
- Project Manager of the Year: Caroline Cattelin
Organized by PharmaTimes, the annual International Clinical Researcher of the Year competition provides a unique opportunity for clinical researchers from all over the world to benchmark their competencies and skills against their peers in an international learning environment. Designed and judged by an independent steering committee of high-level industry leaders, the International Clinical Researcher of the Year has categories for clinical researchers and teams at all stages of their career.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,300 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463 INVESTOR INQUIRIES: InvestorRelations.prahs.com
